XML 61 R45.htm IDEA: XBRL DOCUMENT v3.22.1
Note 4 - Significant Transactions - Allocation of Preliminary Price (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Oct. 20, 2021
Mar. 31, 2022
Mar. 31, 2022
Mar. 31, 2021
Mar. 31, 2020
Goodwill, Ending Balance   $ 291,166 $ 291,166 $ 160,841  
Payments to Acquire Businesses, Net of Cash Acquired, Total     300,793 $ 0 $ 184,102
Customer Relationships [Member]          
Intangible assets, life (Year)   8 years 2 months 12 days      
Intangible assets, life (Year)   8 years 2 months 12 days      
Intellectual Property [Member]          
Intangible assets, life (Year)   7 years 4 months 24 days      
Intangible assets, life (Year)   7 years 4 months 24 days      
Agena [Member]          
Cash and cash equivalents $ 7,544        
Accounts receivable (a) [1] 11,100        
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory [2] 25,480        
Total current assets 44,124        
Property, plant and equipment/noncurrent assets 15,832        
Deferred tax asset 811        
Goodwill, Ending Balance 135,880 [3] $ 135,880 $ 135,880    
Total Assets acquired 361,547        
Accounts payable 2,174        
Unearned revenues 2,713        
Other current liabilities 12,295        
Total current liabilities 17,182        
Deferred tax liability 27,765        
Other noncurrent liabilities 8,263        
Total liabilities assumed 53,210        
Payments to Acquire Businesses, Net of Cash Acquired, Total $ 300,793        
Agena [Member] | Customer Relationships [Member]          
Intangible assets, life (Year) 12 years        
Intangible assets [4] $ 103,800        
Intangible assets, life (Year) 12 years        
Agena [Member] | Intellectual Property [Member]          
Intangible assets, life (Year) 8 years        
Intangible assets [4] $ 45,400        
Intangible assets, life (Year) 8 years        
Agena [Member] | Trade Names [Member]          
Intangible assets, life (Year) 12 years        
Intangible assets [4] $ 15,700        
Intangible assets, life (Year) 12 years        
[1] Trade receivables, net, which is expected to be collected.
[2] Includes $7,462 of inventory step-up, which was amortized entirely within fiscal year 2022. Our evaluation of the valuation of inventory was complete as of March 31, 2022.
[3] Acquired goodwill of $140,022, all of which is allocated to the Clinical Genomics reportable segment, represents the value expected to arise from the value of expanded market opportunities, expected synergies, and assembled workforce, none of which qualify as amortizable intangible assets. The goodwill acquired is not deductible for income tax purposes.
[4] Customer relationships, intellectual property, and tradenames are currently expected to be amortized on a straight line basis over a weighted average 8.3 year period. The identified intangible assets will be amortized on a straight line basis over their useful lives, which approximates the pattern over which the assets' economic benefits are expected to be consumed over time. Amortization expense for customer relationships and tradenames will be amortized to general and administrative expenses; amortization expense for intellectual property will be recorded to cost of revenues. During the period from October 20, 2021 until March 31, 2022, $6,728 of amortization expense was recorded to general and administrative costs and $2,538 of amortization expense was recorded to cost of revenues in the Clinical Genomics Division, including the cumulative effect catch up. Our valuation of intangible assets is considered to be complete as of March 31, 2022. Going forward, we expect to record amortization expense of $3,668 and $1,419 to general and administrative costs and costs of revenues, respectively, each quarter.